BACKGROUND: Despite the considerable advances in the treatment of colorectal cancer, substantial changes in treatment strategies are required to overcome the problems of drug resistance and toxicity. MATERIALS AND METHODS: Combinations of Pan-deacetylase inhibitor LBH589 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) were studied in three colon cancer cell lines, HCT116, colo205, and HT29 (HCT116 and colo205 are TRAIL sensitive, whereas HT29 is TRAIL resistant). RESULTS: It was found that TRAIL-induced cytotoxicity was enhanced by LBH589 cotreatment in the TRAIL-sensitive cell lines, and in the TRAIL-resistant HT29 cell line. The cytotoxicity of low-dose TRAIL plus LBH589 was found to be comparable to that of high-dose TRAIL plus LBH589. Additionally, TRAIL and LBH589 were significantly less toxic to normal UCB mononuclear cells than to the three colon cancer cell lines examined. CONCLUSION: LBH589 enhances TRAIL-induced apoptosis in human colon cancer cell lines, especially those resistant to TRAIL-induced apoptosis.
BACKGROUND: Despite the considerable advances in the treatment of colorectal cancer, substantial changes in treatment strategies are required to overcome the problems of drug resistance and toxicity. MATERIALS AND METHODS: Combinations of Pan-deacetylase inhibitor LBH589 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) were studied in three colon cancer cell lines, HCT116, colo205, and HT29 (HCT116 and colo205 are TRAIL sensitive, whereas HT29 is TRAIL resistant). RESULTS: It was found that TRAIL-induced cytotoxicity was enhanced by LBH589 cotreatment in the TRAIL-sensitive cell lines, and in the TRAIL-resistant HT29 cell line. The cytotoxicity of low-dose TRAIL plus LBH589 was found to be comparable to that of high-dose TRAIL plus LBH589. Additionally, TRAIL and LBH589 were significantly less toxic to normal UCB mononuclear cells than to the three colon cancer cell lines examined. CONCLUSION:LBH589 enhances TRAIL-induced apoptosis in humancolon cancer cell lines, especially those resistant to TRAIL-induced apoptosis.
Authors: Peter M Wilson; Melissa J Labonte; Shelby C Martin; Stephanie T Kuwahara; Anthony El-Khoueiry; Heinz-Josef Lenz; Robert D Ladner Journal: Invest New Drugs Date: 2013-01-09 Impact factor: 3.850
Authors: Marion Flum; Michael Kleemann; Helga Schneider; Benjamin Weis; Simon Fischer; René Handrick; Kerstin Otte Journal: J Cell Commun Signal Date: 2017-09-14 Impact factor: 5.782
Authors: Carina Fischer; Katharina Leithner; Christoph Wohlkoenig; Franz Quehenberger; Alexandra Bertsch; Andrea Olschewski; Horst Olschewski; Andelko Hrzenjak Journal: Mol Cancer Date: 2015-01-21 Impact factor: 27.401
Authors: Аrtem А Аrtykov; Dmitry A Belov; Victoria O Shipunova; Daria B Trushina; Sergey M Deyev; Dmitry A Dolgikh; Mikhail P Kirpichnikov; Marine E Gasparian Journal: Cancers (Basel) Date: 2020-04-30 Impact factor: 6.639
Authors: Belinda Ann Di Bartolo; Siân Peta Cartland; Leonel Prado-Lourenco; Thomas Scott Griffith; Carmine Gentile; Jayant Ravindran; Nor Saadah Muhammad Azahri; Thuan Thai; Amanda Wing Shee Yeung; Shane Ross Thomas; Mary Meltem Kavurma Journal: J Am Heart Assoc Date: 2015-11-16 Impact factor: 5.501
Authors: Giles Vermeire; Elien De Smidt; Peter Casteels; Nick Geukens; Paul Declerck; Kevin Hollevoet Journal: Cancer Gene Ther Date: 2020-07-30 Impact factor: 5.987